scholarly journals Interaction between Vitamin D Receptor Genotype and Estrogen Receptor α Genotype Influences Vertebral Fracture Risk

2003 ◽  
Vol 88 (8) ◽  
pp. 3777-3784 ◽  
Author(s):  
E. M. Colin ◽  
A. G. Uitterlinden ◽  
J. B. J. Meurs ◽  
A. P. Bergink ◽  
M. Van De Klift ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Mineral Density ◽  
Vdr Gene ◽  
Length Polymorphisms ◽  
Osteoporotic Vertebral Fractures ◽  
Vertebral Fracture Risk ◽  
Haplotype 1 ◽  
Restriction Fragment Length

In view of the interactions of vitamin D and the estrogen endocrine system, we studied the combined influence of polymorphisms in the estrogen receptor (ER) α gene and the vitamin D receptor (VDR) gene on the susceptibility to osteoporotic vertebral fractures in 634 women aged 55 yr and older. Three VDR haplotypes (1, 2, and 3) of the BsmI, ApaI, and TaqI restriction fragment length polymorphisms and three ERα haplotypes (1, 2, and 3) of the PvuII and XbaI restriction fragment length polymorphisms were identified. We captured 131 nonvertebral and 85 vertebral fracture cases during a mean follow-up period of 7 yr. ERα haplotype 1 was dose-dependently associated with increased vertebral fracture risk (P < 0.001) corresponding to an odds ratio of 1.9 [95% confidence interval (CI), 0.9–4.1] per copy of the risk allele. VDR haplotype 1 was overrepresented in vertebral fracture cases. There was a significant interaction (P = 0.01) between ERα haplotype 1 and VDR haplotype 1 in determining vertebral fracture risk. The association of ERα haplotype 1 with vertebral fracture risk was only present in homozygous carriers of VDR haplotype 1. The risk of fracture was 2.5 (95% CI, 0.6–9.9) for heterozygous and 10.3 (95% CI, 2.7–40) for homozygous carriers of ERα haplotype 1. These associations were independent of bone mineral density. In conclusion, interaction between ERα and VDR gene polymorphisms leads to increased risk of osteoporotic vertebral fractures in women, largely independent of bone mineral density.

Comparative Efficacy of Alendronate upon Vertebral Bone Mineral Density and Fracture Rates in East Asians Versus Non-East Asians with Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 50 (10) ◽  
pp. 738-746 ◽  
Author(s):  
Yexin Wang ◽  
Gongwei Jia ◽  
Jin Song ◽  
Xiangqing Kong ◽  
Weihong Zhang ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Osteoporosis ◽  
Meta Analysis ◽  
East Asian ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
East Asians ◽  
Vertebral Fracture Risk ◽  
Lumbar Spinal

AbstractBisphosphonates, such as alendronate, have become the most widely used and effective anti-resorptive therapy for postmenopausal osteoporosis. Previous genetic studies suggest that ethnicity may drive differing responses to bisphosphonate therapy in East Asians and non-East Asians. Therefore, the aim of this study was to comparatively evaluate the efficacy of alendronate upon lumbar spinal BMD and vertebral fracture rates in East Asians and non-East Asians with postmenopausal osteoporosis. MEDLINE, EMBASE, and Cochrane CENTRAL were searched for relevant randomized controlled trials (RCTs) comparing the efficacy of alendronate versus placebo (or calcium/mineral and/or Vitamin D or hormone replacement therapy) in primary postmenopausal osteoporotic women. We calculated the weighted mean differences (WMDs) for lumbar spinal BMD and the risk ratios (RRs) for vertebral fracture risk along with their respective 95% confidence intervals (CIs). From an initial set of 445 non-duplicate records, 13 full-text articles were finally included in this meta-analysis consisting of four East Asian RCTs and nine non-East Asian RCTs. Alendronate therapy displayed significant effects in improving lumbar spinal BMD in both East Asians [WMD (95% CI)=5.30 (0.32–10.29), p=0.037] and non-East Asians [WMD (95% CI)=5.73 (3.61–7.85), p=0.000]. Alendronate therapy did not display significant effects upon vertebral fracture risk in East Asians [RR (95% CI)=0.41 (0.06–2.73), p=0.358] but did display a significant effect upon lowering vertebral fracture risk in non-East Asians [RR (95% CI)=0.55 (0.42–0.72), p=0.000]. These findings suggest that ethnicity may affect the efficacy of bisphosphonate therapy in postmenopausal osteoporotic women.

Association of PLXNA2 polymorphisms with vertebral fracture risk and bone mineral density in postmenopausal Korean population

2006 ◽  
Vol 17 (11) ◽  
pp. 1592-1601 ◽  
Author(s):  
J. -Y. Hwang ◽  
J. -Y. Lee ◽  
M. -H. Park ◽  
K. -S. Kim ◽  
K. -K. Kim ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Korean Population ◽  
Mineral Density ◽  
Vertebral Fracture Risk

scholarly journals Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk

2012 ◽  
Vol 23 (7) ◽  
pp. 1877-1887 ◽  
Author(s):  
S.-M. Xiao ◽  
Y. Gao ◽  
C.-L. Cheung ◽  
C. H. Bow ◽  
K.-S. Lau ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Binding Site ◽  
Bone Mineral ◽  
Mineral Density ◽  
Vertebral Fracture Risk

scholarly journals Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy

2002 ◽  
Vol 17 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Somnath Sarkar ◽  
Bruce H. Mitlak ◽  
Mayme Wong ◽  
John L. Stock ◽  
Dennis M. Black ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Mineral Density ◽  
Incident Vertebral Fracture ◽  
Vertebral Fracture Risk

Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk With Raloxifene Therapy

2002 ◽  
Vol 57 (7) ◽  
pp. 446-448
Author(s):  
Somnath Sarkar ◽  
Bruce H. Mitlak ◽  
Mayme Wong ◽  
John L. Stock ◽  
Dennis M. Black ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Mineral Density ◽  
Incident Vertebral Fracture ◽  
Vertebral Fracture Risk

Vertebral Fracture Risk Is Reduced for Women Who Lose Femoral Neck Bone Mineral Density During Teriparatide Treatment

2008 ◽  
Vol 11 (3) ◽  
pp. 465 ◽  
Author(s):  
Nelson B. Watts ◽  
Paul D. Miller ◽  
Robert Marcus ◽  
Peiqi Chen ◽  
Jody Arsenault ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Femoral Neck ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Mineral Density ◽  
Teriparatide Treatment ◽  
Vertebral Fracture Risk

scholarly journals Association of Cdx1 binding site of periostin gene with bone mineral density and vertebral fracture risk

Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S158-S159
Author(s):  
S.-M. Xiao ◽  
Y. Gao ◽  
C.-L. Cheung ◽  
C.H. Bow ◽  
K.-S. Lau ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Binding Site ◽  
Bone Mineral ◽  
Mineral Density ◽  
Vertebral Fracture Risk

scholarly journals Glucocorticoid-Induced Bone Loss Is Associated with Abnormal Intravertebral Areal Bone Mineral Density Distribution

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Louise I. Manning ◽  
Andrew M. Briggs ◽  
Sharon Van Doornum ◽  
Ashwini Kale ◽  
Susan Kantor ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vertebral Fracture ◽  
Bone Loss ◽  
Fracture Risk ◽  
Bone Mineral ◽  
Vertebral Body ◽  
Areal Bone Mineral Density ◽  
Primary Osteoporosis ◽  
Mineral Density ◽  
Vertebral Fracture Risk

Individuals with glucocorticoid-induced osteoporosis experience vertebral fractures at an increased rate and at higher vertebral areal bone mineral density (aBMD) than individuals with primary osteoporosis. Standard posteroanterior- (PA-) projection dual energy X-ray absorptiometry (DXA) lacks the diagnostic sensitivity required for reliable estimation of vertebral fracture risk in individuals. Assessment of subregional vertebral aBMD using lateral-projection DXA may improve the predictive value of DXA parameters for fracture. One hundred and four individuals were recruited and grouped for this study: primary osteoporosis with no history of vertebral fracture (n=43), glucocorticoid-induced bone loss (n=13), and healthy controls (n=48). Standard PA-projection and supine-lateral scans were performed, and lateral scans were analysed according to an established protocol to measure aBMD within 6 subregions. Main effects for subregion and group were assessed and observed, by ANCOVA. Ratios were calculated between subregions and compared between groups, to overcome the potentially confounding influence of variability in subregional geometry. Significantly lower values were observed in the glucocorticoid group for the ratios of (i) anterior subregion: whole vertebral body and (ii) posterior: whole vertebral body when compared to the primary osteoporosis and control groups (P<0.05). Lower anterior subregional aBMD in individuals on glucocorticoid therapy may help to explain the increased vertebral fracture risk in this patient group.

Sign in / Sign up

Export Citation Format

Share Document